We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Oncology Biomarker Testing Current US Practice Baseline and Emerging Trends

Video   Jun 23, 2015

 



About the Speaker
Julia Trosman is co-founder and director of the Center for Business Models in Healthcare, a health services research organization focused on precision medicine and personalized care models. She holds adjunct faculty appointments at the Department of Clinical Pharmacy, the University of California, San Francisco, and Feinberg School Medicine, Northwestern University. Julia’s work is focused on adoption and reimbursement of precision medicine in oncology and other disease areas, as well as development and implementation of personalized care delivery and reimbursement models. In collaboration with the UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Julia researches health care system and reimbursement policy implications of genomic sequencing. She holds an MBA degree from Kellogg School of Management, Northwestern University, and a PhD degree in systems engineering from the Law and Economics Institute (Russia).Abstract
Molecular biomarkers, a cornerstone of precision oncology, are critical for management of a number of cancers. Testing practices are varied and intensely debated, impacting diagnostic quality and affecting pathologists, oncologists and patients. However, little is known about testing approaches used in the US clinical practice. This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers. Taken together, these three cancers represent an epitome of molecular profiling practices. We will discuss these practices as the groundwork for a U.S. practice baseline, in the context of current guidelines, testing challenges and implications for community-based oncology. Finally, we will outline emerging trends in biomarker testing, namely next-generation tumour sequencing, and related adoption and reimbursement implications. 

 
 
 
Advertisement
 

Recommended Videos

What Is a Diagnostic Test Accuracy Review?

Video

Cochrane systematic reviews can help us to make healthcare decisions based on up-to-date research evidence. They are systematic because they search for and analyse evidence in a systematic way, according to predetermined and published methods.

WATCH NOW

Cancer Research During COVID-19

Video

Cancer Research UK (CRUK) scientists share how they have responded to the COVID-19 pandemic, and how CRUK is continuing to support people affected by cancer through life-saving research.

WATCH NOW

The Thermo Scientific Orbitrap Exploris 240 Mass Spectrometer Fast Tracks Your Path to High-confidence Discovery and Identification

Video

Meet the Orbitrap Exploris 240 mass spectrometer: leading performance, application versatility and intelligent data acquisition enable exceptional data quality that is synonymous with Thermo Scientific Orbitrap technology.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Diagnostics Genomics Research Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE